(notes inside)
Stansberry Research

Reader,

I learned so much this evening from Dr. David Eifrig and Dave Lashmet, and I hope you did, too.

We received an overwhelming number of questions from readers about how to purchase the stock Dave Lashmet told you about tonight.

Dave believes this little-known company will revolutionize cancer treatment… and will see its stock double (or even more) in the next few weeks… as the company receives global regulatory approval.

The only way to get the stock's ticker symbol and the full write-up is to sign up for Stansberry Venture Technology (by midnight tonight for best results.)

Please note: Venture is best suited for you if you love early-stage opportunities… are curious about the future of our society… and the best investments along the way...

Folks like subscriber Ron S., who recently told us he's up about $35,000.

Dave’s not interested in "tire-kickers"… who can't afford to speculate and aren't willing to understand his research.

One full year of Venture Technology normally costs $5,500.

If that sounds like too much money, I'm sorry. This isn't for you.

The reality is, Venture Technology is a steal at $5,500 a year.

In fact, I'm certain we could charge upwards of $20,000 a year and hundreds of individuals and institutions would happily pay for it. It pays just to be "in the club." 

It would cost you $400,000 to do this research on your own, and you'd have to travel the world all year looking for new investment opportunities, as Dave does.

Consider: A $5,000 investment in just one of Dave's 8 different doubles could have already paid for your subscription.

But tonight only, given the serious nature of the topic, we're willing to make you a special offer, which will expire at midnight.

You can review all the terms of tonight's special offer here.

As Porter Stansberry says, "Dave's research has identified more than a dozen companies whose groundbreaking technology eventually drove their share prices up 10-times or more over the course of his career." 

The window to invest in this particular story is closing quickly, so I urge you to act prudently, but quickly, to make the biggest gain on what could be the most successful cancer treatment our society has ever seen.

Just remember, this offer expires at midnight tonight.

Come 12:01 a.m., the price will increase.

Click here to join Stansberry Venture.

Regards,

Jared Kelly
Managing Director
Stansberry Research

P.S. If you'd prefer to place your order on the phone, call right now before midnight, to receive the biggest discount you may ever see: 800-961-5843.



All contents of this e-mail are copyright 2017 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.

DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.

You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to info@stansberrycustomerservice.com.

To unsubscribe from this mailing, click here: Unsubscribe